MedMira Launches Rapid HIV Test into Retail OTC Market Ships New MiraCare(TM) OTC Product to Retail Pharmacies HONG KONG, Jan. 24 /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ:MMIRF) the global market leader in rapid flow- through diagnostic technology, today announced the launch of its MiraCare(TM) HIV Rapid Antibody Test, its first Over-The-Counter (OTC) test, into the global marketplace, starting with Hong Kong and Macao, People's Republic of China. MiraCare(TM) will be distributed to pharmacies in these regions by Goodman Medical Supplies Ltd., a well-established medical supply distributor. MiraCare(TM) became available in pharmacies today. This new finger-stick whole blood rapid HIV test is built on MedMira's proven, unique platform used in its market-leading MiraWell(TM) and Reveal(TM) product lines. Each MiraCare(TM) test is sold as a complete test package with all components required for an individual to conduct the test quickly; with results showing in just three minutes. "Launching this new product line into the OTC market is a pivotal moment in MedMira's history," said Stephen Sham, Chairman and Chief Executive Officer of MedMira Inc. "The introduction of our new MiraCare(TM) line of rapid tests into point-of-testing settings will serve as a model for future expansion of this product into OTC markets in China, the rest of Asia, and ultimately around the world as these markets become more prepared for an OTC rapid HIV test." Sham continued, "With almost 40 years of experience, Goodman Medical Supplies Ltd. is the ideal partner to join MedMira in opening this Hong Kong and Macao market through its experienced sales force and extensive knowledge and networks in these regions." Collen Chan, Managing Director of Goodman Medical Supplies Ltd. said, "Over the past year, we have dedicated substantial resources to identifying the best-suited rapid HIV test for our retail pharmacy sector. Of the rapid HIV tests available in China, MedMira was the only manufacturer that could deliver a quality product with a simple test procedure and a truly rapid and accurate test result in less than three minutes." Chan continued, "In addition, the fact that the recent China Centres for Disease Control (CDC) evaluation proved MedMira's test to be number one, and that MedMira is the only rapid HIV test manufacturer to hold regulatory approvals in China, the United States and Canada shows us that we have identified the best company and product for our OTC market." About Goodman Medical Goodman Medical Supplies Ltd. ("Goodman Medical") was established in 1966 and is one of the pioneers of medical suppliers in the healthcare market of Hong Kong. It offers a variety of medical products for hospital, community and personal care. Goodman Medical prides itself with a goal of sharpening competitiveness to meet the rapidly changing challenges of the healthcare market, and to serve customers with the highest value of service. It sets its quality standards high, and as a result, distributes only the highest caliber of medical products. Over the years, Goodman Medical has established itself to be the partner of choice for healthcare services. Further information about Goodman Medical Supplies Ltd. is available on its website: http://www.goodmanmedical.org/ About MedMira MedMira is the leading global manufacturer and marketer of in vitro flow-though rapid diagnostic tests for the clinical laboratory market. MedMira's tests provide reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV. The United States FDA and the SFDA in the People's Republic of China have approved MedMira's Reveal(TM) G2 and MiraWell(TM) Rapid HIV Tests, respectively. For more information visit MedMira's website at http://www.medmira.com/. MedMira's Reveal(TM) G2 and MiraWell(TM) rapid HIV tests are currently used in clinical laboratories and hospitals where professional counseling and patient treatment are immediately available. MedMira markets its rapid tests worldwide in such countries as the United States, Canada, South Africa and China. Its corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office in Beijing, China. This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. DATASOURCE: MedMira Inc. CONTACT: Media Contact: Investor Relations: Dr. James Smith: (902) 450-1588 or e-mail:

Copyright